{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Gliomas&page=35", "query": { "condition": "Recurrent Gliomas", "page": 35 }, "page_size": 10 }, "pagination": { "page": 35, "page_size": 10, "total_count": 1033, "total_pages": 104, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Gliomas&page=36&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Gliomas&page=34&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T05:05:19.454Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02047214", "title": "Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "TPI 287", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cortice Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2014-01", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2018-01-31", "last_synced_at": "2026-10-22T05:05:19.454Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT02047214" }, { "nct_id": "NCT00953121", "title": "Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Glioma" ], "interventions": [ { "name": "bevacizumab and CPT-11 and Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Annick Desjardins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2009-09", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2013-09-16", "last_synced_at": "2026-10-22T05:05:19.454Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00953121" }, { "nct_id": "NCT00003234", "title": "Vinorelbine in Treating Children With Recurrent or Refractory Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Neuroblastoma", "Sarcoma" ], "interventions": [ { "name": "vinorelbine tartrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 50, "start_date": "1998-05", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2014-07-28", "last_synced_at": "2026-10-22T05:05:19.454Z", "location_count": 200, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 149 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003234" }, { "nct_id": "NCT03893487", "title": "Fimepinostat in Treating Brain Tumors in Children and Young Adults", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Diffuse Intrinsic Pontine Glioma", "Recurrent Anaplastic Astrocytoma", "Recurrent Glioblastoma", "Recurrent Malignant Glioma", "Recurrent Medulloblastoma" ], "interventions": [ { "name": "Fimepinostat", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Sabine Mueller, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "3 Years to 39 Years" }, "enrollment_count": 30, "start_date": "2019-08-07", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-22T05:05:19.454Z", "location_count": 18, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03893487" }, { "nct_id": "NCT00002971", "title": "O(6)-Benzylguanine in Treating Patients With Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "O6-benzylguanine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "1997-06-19", "completion_date": "2009-01-01", "has_results": false, "last_update_posted_date": "2018-06-27", "last_synced_at": "2026-10-22T05:05:19.454Z", "location_count": 9, "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002971" }, { "nct_id": "NCT03598244", "title": "Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Diffuse Intrinsic Pontine Glioma", "Recurrent Malignant Glioma", "Recurrent Medulloblastoma", "Recurrent Primary Central Nervous System Neoplasm", "Refractory Diffuse Intrinsic Pontine Glioma", "Refractory Malignant Glioma", "Refractory Medulloblastoma", "Refractory Primary Central Nervous System Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Savolitinib", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Years to 21 Years" }, "enrollment_count": 41, "start_date": "2018-11-27", "completion_date": "2027-05-27", "has_results": true, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-22T05:05:19.454Z", "location_count": 11, "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03598244" }, { "nct_id": "NCT00378235", "title": "Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Malignant Glioma" ], "interventions": [ { "name": "IL13-PE38QQR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "INSYS Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2014-11-13", "last_synced_at": "2026-10-22T05:05:19.454Z", "location_count": 10, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00378235" }, { "nct_id": "NCT04003649", "title": "IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Glioblastoma", "Refractory Glioblastoma" ], "interventions": [ { "name": "IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2019-12-02", "completion_date": "2026-09-26", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-10-22T05:05:19.454Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04003649" }, { "nct_id": "NCT00004004", "title": "Procarbazine in Treating Patients With Recurrent Brain Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "procarbazine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New Approaches to Brain Tumor Therapy Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-07", "completion_date": "2003-08", "has_results": false, "last_update_posted_date": "2013-06-21", "last_synced_at": "2026-10-22T05:05:19.454Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004004" }, { "nct_id": "NCT04478279", "title": "A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma", "Melanoma Stage IV", "Breast Cancer", "Prostate Cancer", "Glioblastoma Multiforme", "GBM", "Brain Cancer", "Metastatic Breast Cancer", "Metastatic Melanoma", "Metastatic Prostate Cancer", "Melanoma Recurrent", "Prostate Cancer Metastatic", "Recurrent Glioblastoma", "Newly Diagnosed Glioblastoma" ], "interventions": [ { "name": "ST101", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Sapience Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2020-07-01", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-10-22T05:05:19.454Z", "location_count": 7, "location_summary": "San Francisco, California • Denver, Colorado • Warrenville, Illinois + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Warrenville", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04478279" } ] }